Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LNG Energy Announces Signing of Hydrocarbon Productive Participation Contracts (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Lobe Sciences Ltd. C.LOBE

Alternate Symbol(s):  LOBEF

Healthcare Drug Manufacturers - Major
Lobe Sciences is a leading “BioPsychedelic” company entering clinical stage development focused on transforming psychedelic medicine to benefit patients of all ages. We are engaged in research and development using psychedelic and non-psychedelic compounds targeting the 5HT2 receptor family. Our team is made up of biotech executives who collectively have managed the development and regulatory... see more

Recent & Breaking News (CSE:LOBE)

Lobe Sciences Provides Company Review of 2023

Business Wire January 8, 2024

Lobe Sciences Provides Update on L-130 Clinical Program

Business Wire December 7, 2023

Lobe Sciences Provides Update on L-130 Oral Psilocin Compound

Business Wire December 5, 2023

Lobe Sciences, Ltd. Announces The Appointment Of Mathew Lee As CFO

Business Wire September 18, 2023

Lobe Sciences, Ltd. Announces Amendment to the Acquisition of Altemia(TM) & Company

Business Wire September 14, 2023

Lobe Sciences Announces Additional Details Regarding the Acquisition of Altemia(TM) & Company

Newsfile June 30, 2023

Lobe Sciences Initiates Phase 1 Clinical Trial of L-130

Business Wire June 27, 2023

Lobe Sciences Appoints Baxter Phillips III, MBA as Chief Operating Officer

Business Wire June 7, 2023

Lobe Sciences Announces Commercial Distribution Agreement With Pentec Health for US Launch of Altemia(TM)

Business Wire May 17, 2023

Lobe Sciences, Ltd. Provides Update on Vitamind

Newsfile April 21, 2023

Lobe Sciences, Ltd. Announces the Acquisition of Altemia(TM) & Company

Newsfile April 18, 2023

Lobe Sciences to Present at Sequire Cannabis & Psychedelics Conference April 5, 2023

Newsfile April 4, 2023

Lobe Sciences Ltd. Announces That The Drug Enforcement Administration Has Issued The Initial 2023 Quota Allowing Export Of L-130

Newsfile March 22, 2023

Lobe Sciences Ltd. Announces Exclusive Collaboration with Quality Chemical Laboratories LLC

Newsfile February 21, 2023

Lobe Sciences, Ltd. Announces USD$250,000 Convertible Note Financing and Warrant Issuance

Newsfile February 10, 2023

Lobe Sciences Congratulates Australia for Becoming the First Nation to Approve the Medicinal Use of Psilocybin and MDMA

Newsfile February 6, 2023

Lobe Sciences (CSE:LOBE) signs agreement with Integrative Headache Medicine of New York

Azuka Onwuka January 26, 2023

Lobe Sciences, Ltd. Enters Collaborative Clinical Research Agreement with Integrative Headache Medicine of New York to Study the Effects of L-130 in the Treatment of Chronic Cluster Headache

Newsfile January 26, 2023

Lobe Sciences Board of Directors Elects to Receive Shares in Lieu of Cash for All Board Fees

Newsfile January 23, 2023

Lobe Sciences Provides Update For 2023 Milestones

Newsfile January 18, 2023